C0064761||Leonurine
C0020429||Hyperalgesia
C0026809||Mice
C0341858||Adenomyosis
C0341858||Adenomyosis
C2699153||invasion
C0227848||endometrial glands
C0927195||stroma
C0027088||myometrium
C0017411||gynecological disorder
C0684224||report
C0064761||leonurine
C0025925||ICR mice
C0341858||adenomyosis
C0039286||tamoxifen
C0039286||tamoxifen
C0030193||pain
C0026809||mice
C0022885||tests
C0026809||mice
C0064761||leonurine
C0087111||treatment
C0064761||leonurine
C0087111||treatment
C0042291||valproic acid
C0042291||valproic acid
C0087111||treatment
C0042444||vehicle
C0087111||treatment
C0220825||evaluated
C0022885||tests
C0205125||depth
C0521387||myometrial
C0332448||infiltration
C0487602||staining
C0034833||progesterone receptor
C0034833||progesterone receptor
C1567061||nuclear factor-ÎºB phosphorylated-p65
C1567061||phosphorylated-p65
C1447194||cyclooxygenase-2
C1447194||cyclooxygenase-2
C3849099||oxytocin receptor
C3849099||oxytocin receptor
C0220825||evaluated
C0021044||immunohistochemistry
C0521387||myometrial
C0332448||infiltration
C0039286||tamoxifen
C0087111||treatment
C0341858||adenomyosis
C0064761||Leonurine
C0087111||treatment
C0020429||hyperalgesia
C0521387||myometrial
C0332448||infiltration
C0487602||staining
C1567061||phosphorylated-p65
C1447194||cyclooxygenase-2
C3849099||oxytocin receptor
C1171362||protein expressions
C0064761||leonurine
C0020429||hyperalgesia
C0026809||mice
C0341858||adenomyosis
C0013081||down-regulating
C1171362||expressions
C1567061||p-P65
C1447194||cyclooxygenase-2
C3849099||oxytocin receptor
C0341858||adenomyosis